Clear Search Filters
Search Medical Condition
Please enter condition
Please choose location from dropdown

Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for the closest city to find more detailed information on a research study in your area.

RESULTS

Found (589) clinical trials

Safety PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

This is a three-part Phase 2 study Part 1: (MT-3724 Dose Escalation) Define the maximum tolerated dose (MTD) of MT-3724 [Completed] Part 2: (MTD Expansion Cohort) Confirm the safety and tolerability of the MTD of MT-3724 in the MTD Expansion Cohort. Part 3: (Phase 2 MTD Expansion Cohort) Determine the …

Phase

0.0 miles

Learn More »

A Study of Carfilzomib Lenalidomide Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.

Phase

2.14 miles

Learn More »

A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has …

Phase

2.62 miles

Learn More »

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Principal Investigators: The principal investigators (PIs) will be transplant physicians at all participating U.S. transplant centers. Study Design: This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Primary Objective: The primary objective of …

Phase N/A

2.62 miles

Learn More »

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

This is a multicenter, single-arm study designed to assess the operating characteristics of the EsoGuard diagnostic assay performed on distal esophageal mucosal cells collected using the EsoCheck cell collection device, compared to the gold standard, for the screening of BE with and without dysplasia and for esophageal adenocarcinoma (EAC), in …

Phase N/A

2.62 miles

Learn More »

Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety, tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an anti-CD47 antibody, in subjects with advanced relapsed or refractory solid tumors and lymphoma. The …

Phase

2.62 miles

Learn More »

Project: Every Child for Younger Patients With Cancer

PRIMARY OBJECTIVES: I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer. II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic …

Phase N/A

2.62 miles

Learn More »

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and …

Phase

2.62 miles

Learn More »

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in participants with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma intolerant of prior ibrutinib and/or acalabrutinib treatment, compared with their ibrutinib and/or acalabrutinib intolerance …

Phase

2.62 miles

Learn More »

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

This is a multicenter, open-label, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV+ PTLD in the setting of SOT after failure of rituximab and rituximab plus chemotherapy (SOT cohort) or HCT after failure of rituximab (HCT cohort). Enrollment will be preceded by …

Phase

3.13 miles

Learn More »